Cancer Biotech Closes NOMAD Merger, Renames Itself an Energy Company
Turnaround
Company Background
LIXTE Biotechnology Holdings spent most of the past decade developing LB-100, a first-in-class PP2A inhibitor in clinical trials for ovarian, colorectal, and soft-tissue cancers. As recently as December 2025, the company expanded its collaborative study with GlaxoSmithKline and MD Anderson Cancer Center, doubling enrollment from 21 to 42 subjects and announcing a new pre-clinical partnership with the Netherlands Cancer Institute.
The company's financial position has been fragile. In July 2025, Nasdaq notified LIXTE that it had violated the exchange's minimum stockholders' equity rule, and the company scrambled to raise approximately $6.5 million across two offerings to regain compliance. Nasdaq restored LIXTE's listing status on July 15, 2025, but placed it under a one-year Panel Monitor through July 15, 2026. New CEO Geordan Pursglove had arrived in June 2025, and a near-total overhaul of the board and senior management followed over the subsequent months, culminating in a headquarters relocation to Boca Raton, Florida.
By August 2025, the board had approved allocating up to 50% of its treasury to cryptocurrency and purchased approximately $2.6 million in Bitcoin and Ethereum. By June 2026, the company had abandoned its pharmaceutical identity entirely.
What Was Disclosed
NOMAD Transportable Power Systems became a wholly owned subsidiary of LIXTE on July 1, 2026, when a Certificate of Merger was filed with the Delaware Secretary of State. As merger consideration, LIXTE issued 2,992,041 shares of common stock and 50,366.07 shares of newly designated Series D Non-Voting Convertible Preferred Stock. Each Series D share carries a liquidation value of $1,000 and is convertible into 1,000 shares of common stock at a conversion price of $1.00 per share — meaning the preferred tranche alone represents up to approximately 50.4 million potential common shares. NOMAD stockholders who were not accredited investors received cash instead of stock, priced at the 60-day VWAP of $5.57 per share.
The Series D shares are non-voting and cannot be converted until existing LIXTE shareholders approve the conversion at a stockholder meeting, which the company is required to hold within 60 days of closing — on or about September 4, 2026. If stockholder approval is not obtained within one year of issuance, the preferred shares begin accruing a 7% annual cumulative cash dividend on the $1,000 liquidation value, payable quarterly. Alongside the merger, LIXTE entered into a Registration Rights Agreement obligating it to file a resale registration statement within 30 days after the later of stockholder approval, completion of a NOMAD audit, or the six-month anniversary of closing. NOMAD's financial statements and pro forma financials were not included in the filing and are due by amendment within 71 days.
The company simultaneously changed its name to Nomad Power Solutions, Inc., effective July 3, 2026, and its Nasdaq ticker to NMAD, effective July 6, 2026. John Travaglini, NOMAD's CEO, joined the LIXTE board effective July 1. The board also amended its bylaws to remove the provision dividing directors into three staggered classes, making all directors subject to annual election.
Why It Matters
The $1.00 per share conversion price on the Series D preferred is the central structural fact for existing shareholders. The 60-day VWAP used to cash out NOMAD's non-accredited stockholders was $5.57 — more than five times the conversion price embedded in the preferred stock issued to accredited NOMAD investors. If shareholders approve the conversion at the September meeting, the approximately 50.4 million new common shares created by the preferred would represent substantial dilution to the existing share base. The September vote is therefore not a formality; a Stockholder Support Agreement was executed at closing, in which certain existing LIXTE stockholders committed their proxies to vote in favor of conversion and related matters.
The pace of the transaction warrants attention. The strategic pivot was announced June 1. The $16.6 million registered direct offering closed June 4 — sized to just clear the merger's $16.5 million minimum cash closing condition. The merger agreement was signed June 11, a $6.5 million secured promissory note was extended to NOMAD on June 17 to retire its existing debt and fund working capital, and the deal closed July 1. From pivot announcement to close: 30 days. The promissory note, secured by a first-priority lien on substantially all of NOMAD's assets, was structured to offset against merger consideration at closing rather than be repaid separately.
NOMAD's commercial story rests entirely on management projections. The press release describes approximately 175% revenue growth in 2025 and projects approximately 135% growth in 2026, with more than 30 active customer engagements across North America. None of those figures have been subject to an independent audit filed with the SEC — that audit, and related pro forma financials showing the combined entity, will not be available until the 71-day amendment window closes. The Nasdaq Panel Monitor period that began in July 2025 expires on July 15, 2026, just two weeks after the merger closed under the new corporate identity.